Loading...

BSX BOSTON SCIENTIFIC CORP Management Changes 8-K Filing

BSTN

BSX

BOSTON SCIENTIFIC CORP

(BSX)

2026 8-K

Clinical Trial Results

Credit Agreements Update

Board Changes & Buyback

Director Departure

Financial Results Released

Merger Announcement

Boston Scientific Acquisition

Bonus Plan Update

Director Departure

Financial Results

Management Change

Financial Statements

Product Discontinuation

Financial Statements

Senior Notes Offering

Board Departure

Financial Results

Court Settlement

Executive Compensation

Acquisition Completed

Clinical Trial Resumption

Q3 Financial Results

Appointment of Director

Earnings Reports

Appointment of Director and...

By-Laws Amendment

Financial Results Announcement

Underwriting Agreement for ...

Appointment of Officers

Financial Results Announcement

Merger Agreement

Acquisition of Axonics, Inc.

Departure of Directors and ...

Earnings Reports

Earnings Reports

Appointment of Directors

Conversion of Preferred Stock

Annual Meeting of Stockholders

Financial Results Announcement

External Links:

On February 18, 2026, Boston Scientific appointed Catherine R. Smith and Christophe P. Weber as directors, and approved increasing their stock buyback program by $4 billion to a total of $5 billion.

AI Assistant

BOSTON SCIENTIFIC CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.